Walmart reported Q2 results with US comparable sales growth hitting its lowest point since 2020, primarily due to pharmacy deflation. Despite beating EPS and sales estimates, the company's Q3 guidance and full-year sales outlook fell below consensus, leading to a significant premarket stock decline.
Walmart's Q2 earnings report revealed a significant slowdown in US comparable sales growth, reaching its weakest pace since 2020, largely attributed to pharmacy deflation from new fair price regulations. While the company beat Q2 EPS and sales estimates, its Q3 guidance and full-year sales outlook were below analyst consensus, signaling potential headwinds. This news is a negative catalyst for WMT stock, as evidenced by the premarket decline, indicating investor concern over future growth prospects despite efforts like price rollbacks and attracting higher-income households. The short-term implication is downward pressure on WMT, while the long-term impact depends on how effectively Walmart can mitigate pharmacy headwinds and leverage e-commerce and membership growth.